Chronic pain affects hundreds of millions of people worldwide, and for decades opioids have been among the most widely prescribed tools for managing it, despite well-documented risks of addiction and dependency. That landscape is shifting. A wave of new pharmacological approaches, non-drug therapies and digital interventions is reshaping how clinicians think about pain relief, and a landmark FDA approval in early 2025 may mark the most significant turning point in a generation.
Pain science has also evolved. Researchers now understand chronic pain as a complex condition involving dysregulated pain processing in the nervous system, central sensitization and interactions between the immune and nervous systems, rather than simply a response to tissue damage. That shift in understanding is driving a new generation of treatments designed to target the biological roots of pain rather than simply suppress its symptoms.
A first-in-class drug changes the conversation
The most significant recent development came on January 30, 2025, when the FDA approved suzetrigine, sold under the brand name Journavx, the first non-opioid pain drug to receive approval in roughly 20 years. The drug works by selectively blocking a sodium channel in peripheral sensory neurons called NaV1.8, interrupting pain signals before they reach the spinal cord and brain. Because it acts on the peripheral nervous system rather than the brain itself, it carries none of the addictive potential associated with traditional opioids.
Clinical trials in patients recovering from surgical procedures showed meaningful pain relief significantly faster than placebo, with the drug demonstrating its effectiveness across two large phase III studies. The approval represents a genuine pharmacological breakthrough, offering a new class of option for patients with moderate to severe acute pain who need relief without the risks that have made opioid prescribing so controversial.
Other promising drug approaches
Researchers have also been exploring drugs that target nerve growth factor, a protein that plays a key role in pain sensitization. Monoclonal antibodies designed to block this protein showed promising results in clinical trials for osteoarthritis pain but ran into serious safety concerns, including cases of rapidly progressive joint destruction. The FDA’s advisory committee ultimately determined that the risks outweighed the benefits, and the development program for the leading candidate in this class was discontinued.
Anti-inflammatory biologics targeting specific immune proteins involved in pain signaling represent another active area of research. Some of these drugs have shown benefits for patients whose chronic pain has a measurable inflammatory component, particularly certain types of lower back pain, though results have been inconsistent across broader patient populations. Researchers are working to identify which patients are most likely to benefit, with the goal of matching treatments to individual inflammatory profiles.
Non-drug therapies gaining ground
Beyond pharmacology, a range of non-drug approaches is increasingly being incorporated into chronic pain treatment. Transcutaneous electrical nerve stimulation, which uses low-voltage electrical currents to interrupt pain signaling in peripheral nerves, has demonstrated clinical effectiveness in conditions including fibromyalgia and osteoarthritis, though repeated use can reduce its effectiveness over time.
Cognitive behavioral therapy and mindfulness-based interventions address the psychological dimensions of chronic pain, improving how patients cope with pain and reducing the tendency to catastrophize symptoms in ways that can amplify suffering. Acupuncture has also shown pain-modulating effects through mechanisms involving local neurochemical release and activation of the brain’s own descending pain-inhibition pathways.
Digital tools including virtual reality programs, telerehabilitation platforms and app-based pain management systems have shown modest early results, though the evidence base remains limited and researchers caution against overstating their current clinical utility.
A shift toward individualised care
No single therapy works for every patient, and researchers are increasingly clear that the future of chronic pain treatment lies in personalized, multimodal approaches that combine pharmacological and non-pharmacological strategies tailored to the individual. Genetic variations in pain sensitivity mean that what works powerfully for one patient may offer little relief to another.
The convergence of new drug classes, better understanding of pain biology and expanding non-drug options is giving patients and clinicians more tools than ever before. The opioid era is not over, but its dominance in pain medicine is beginning to genuinely recede.
